Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer

Alfredo Tartarone; Vittoria Lapadula; Concetta Di Micco; Gemma Rossi; Carlotta Ottanelli; Andrea Marini; Roberta Giorgione; Katia Ferrari; Martina Catalano; Luca Voltolini; Enrico Mini; Giandomenico Roviello

doi:10.3389/fonc.2021.632256

Frontiers in Oncology (May 2021)

Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer

Alfredo Tartarone,
Vittoria Lapadula,
Concetta Di Micco,
Gemma Rossi,
Carlotta Ottanelli,
Andrea Marini,
Roberta Giorgione,
Katia Ferrari,
Martina Catalano,
Luca Voltolini,
Enrico Mini,
Giandomenico Roviello

Affiliations

Alfredo Tartarone: Department of Onco-Hematology, Division of Medical Oncology IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy
Vittoria Lapadula: Department of Onco-Hematology, Division of Medical Oncology IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy
Concetta Di Micco: Division of Medical Oncology, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
Gemma Rossi: School of Human Health Sciences, University of Florence, Florence, Italy
Carlotta Ottanelli: School of Human Health Sciences, University of Florence, Florence, Italy
Andrea Marini: School of Human Health Sciences, University of Florence, Florence, Italy
Roberta Giorgione: School of Human Health Sciences, University of Florence, Florence, Italy
Katia Ferrari: Respiratory Medicine, Careggi University Hospital, Florence, Italy
Martina Catalano: School of Human Health Sciences, University of Florence, Florence, Italy
Luca Voltolini: Thoracic Surgery Unit, Careggi University Hospital, Florence, Italy
Enrico Mini: Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy
Giandomenico Roviello: Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy

DOI: https://doi.org/10.3389/fonc.2021.632256
Journal volume & issue: Vol. 11

Abstract

Read online

In the last few years the advent of targeted therapies against oncogenic drivers significantly improved the survival of non small cell lung cancer (NSCLC) patients with a favourable toxicity profile. Therefore, genetic testing, including at least EGFR mutations and ALK/ROS1 rearrangements, should be performed in all NSCLC patients (in particular with adenocarcinoma) who received a diagnosis of advanced disease. This review focuses on novel druggable oncogenic drivers, such as MET exon 14 mutations/MET amplification, RET fusions, BRAF V600E mutations, KRAS G12C mutations, NTRK rearrangements, and HER2 alterations.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords